Johnson & Johnson Increases Dividend: What Shareholders Need To Know

Printed on Could third, 2023 by Aristofanis Papadatos

Johnson & Johnson (JNJ) not too long ago raised its dividend by 5%, and thus it has now raised its dividend for 61 consecutive years. This is without doubt one of the longest dividend development streaks within the investing universe, which is a testomony to the corporate’s enterprise mannequin’s power and stable execution. Additionally it is value noting that the inventory has underperformed the S&P 500 by a large margin this yr, because it has shed 7% whereas the index has rallied 8%. Consequently, the inventory has turn out to be enticing. On this article, we are going to analyze the prospects of this best-of-breed pharmaceutical large.

You’ll be able to obtain an Excel spreadsheet with the total listing of all 68 Dividend Aristocrats (with extra monetary metrics akin to price-to-earnings ratios and dividend yields) by clicking the hyperlink beneath:

Enterprise Overview

Based in 1886, Johnson & Johnson is a diversified healthcare firm and a pacesetter within the space of prescription drugs (~54% of gross sales), medical gadgets (~30% of gross sales), and client merchandise (~16% of gross sales).

Supply: Investor Presentation

Johnson & Johnson has 28 manufacturers/pharmaceutical platforms that generate greater than $1 billion in annual revenues. The corporate is a pacesetter in its markets, because it generates roughly 70% of its gross sales from the Nr 1 or Nr 2 market share place.

Furthermore, Johnson & Johnson is the fifth-largest firm within the U.S. and the eighth-largest firm on this planet within the complete quantity spent on Analysis & Improvement (R&D). Because of its exemplary R&D division, the corporate has a powerful development document. Johnson & Johnson grew its adjusted working earnings for 36 consecutive years till 2020, when the pandemic prompted a benign 7% lower in its earnings per share. A 7% lower within the earnings per share throughout one of many fiercest downturns in historical past is a testomony to the corporate’s resilience to recessions. Johnson & Johnson has emerged stronger from this disaster, with document earnings per share in 2021 and 2022.

Johnson & Johnson at the moment enjoys constructive enterprise momentum. Because of stable development in all its enterprise segments, it grew its operational gross sales by 9.0% over the prior yr’s quarter.

Supply: Investor Presentation

Prescription drugs, medical gadgets, and client merchandise grew their operational gross sales by 7.2%, 11.0%, and 11.3%, respectively. Adjusted earnings per share edged up solely marginally, from $2.67 to $2.68, however they exceeded the analysts’ estimates by $0.18.

Notably, Johnson & Johnson has exceeded the analysts’ earnings-per-share estimates for 20 consecutive quarters. That is undoubtedly a powerful efficiency document, which confirms that the pharmaceutical large enjoys sustained enterprise momentum. Because of this momentum, administration not too long ago raised its steering for the earnings per share this yr from $10.45-$10.65 to $10.60-$10.70. On the mid-point, the brand new steering implies 5% development of earnings per share over the prior yr to a brand new all-time excessive.

Johnson & Johnson has grown its common earnings per share by 7.0% per yr over the past decade. Given the dedication of the pharmaceutical large on investing closely in its R&D division and its constant development document, we anticipate the corporate to develop its backside line by about 6% per yr on common over the following 5 years.

Dividend

On April 18th, 2023, Johnson & Johnson introduced a 5% dividend increase. Consequently, the corporate has now grown its dividend for 61 consecutive years and is at the moment providing a 2.9% ahead dividend yield. This yield could seem lackluster to most income-oriented traders, however it is very important be aware that this yield is a virtually 10-year excessive for this premium inventory. As a result of distinctive efficiency document of Johnson & Johnson and its dependable development trajectory, it’s uncommon to discover a inventory with a a lot larger dividend yield.

Johnson & Johnson has all the time been a money stream producing machine, as its unparalleled product portfolio has all the time generated extreme free money flows, which have extremely rewarded the shareholders. The identical was evident within the newest quarter.

Supply: Investor Presentation

Within the first quarter, Johnson & Johnson invested $3.6 billion in its R&D division, whereas it additionally distributed $2.9 billion in dividends and spent $2.5 billion on share repurchases. Administration has made it clear that it prioritizes reinvesting earnings within the enterprise with a purpose to develop organically and carry out high-return acquisitions over shareholder distributions. Thanks to those priorities, the corporate has achieved its spectacular development document. Even higher, regardless of the fabric investments in its enterprise, the corporate has all the time generated extreme free money flows and thus it has simply remained one of the crucial well-liked shares within the income-oriented investing group.

The corporate is at the moment dealing with a menace because of the quite a few pending lawsuits associated to the antagonistic well being impression of talc on hundreds of individuals. Johnson & Johnson is attempting to switch all of the liabilities from this subject to a separate division, thus attempting to guard itself from the impact of those liabilities. This follow has turn out to be fairly frequent in recent times however the Division of Justice has not accepted this technique of Johnson & Johnson to this point. Subsequently, there may be excessive uncertainty over the ultimate impression of the hundreds of lawsuits on Johnson & Johnson.

Alternatively, Johnson & Johnson has a rock-solid stability sheet. It is without doubt one of the extraordinarily few corporations that pay completely no curiosity expense whereas its internet debt is just $84 billion, which is simply 20% of the inventory’s market capitalization.

Furthermore, Johnson & Johnson has proved primarily proof against recessions because of the power of its manufacturers and the important nature of its merchandise. Whereas most corporations incurred a collapse of their earnings within the Nice Recession, Johnson & Johnson saved rising its earnings and its dividend all through that disaster.

Given the wholesome payout ratio of 45% of Johnson & Johnson, its rock-solid stability sheet, its resilience to recessions, and its dependable development trajectory, traders ought to relaxation assured that the corporate will proceed elevating its dividend for a lot of extra years. Johnson & Johnson has grown its dividend by 6% per yr on common over the past decade and over the past 5 years. As it’s prone to develop its earnings per share at an analogous tempo within the upcoming years, traders can fairly anticipate the dividend of the inventory to proceed rising at its historic tempo within the upcoming years.

Closing Ideas

Johnson & Johnson has underperformed the broad market by a large margin this yr, primarily because of the uncertainty ensuing from the corporate’s quite a few pending lawsuits. Consequently, the inventory has turn out to be enticing, providing a virtually 10-year excessive dividend yield. Because of its rock-solid stability sheet and the power of its manufacturers, the pharmaceutical large can endure the continued downturn and get well strongly each time the lawsuits are settled. Subsequently, the inventory is prone to extremely reward long-term traders, who can wait patiently for the storm to go and stay targeted on the stable fundamentals of this best-of-breed inventory.

In case you are fascinated with discovering high-quality dividend development shares and/or different high-yield securities and revenue securities, the next Certain Dividend sources will likely be helpful:

Excessive-Yield Particular person Safety Analysis

Different Certain Dividend Assets